General Announcement::Clarification of Press Release on 1 July 2019 and Revised Press Release

Issuer & Securities

Issuer/ Manager
BIOLIDICS LIMITED
Securities
BIOLIDICS LIMITED - SGXE89830751 - 8YY
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
02-Jul-2019 11:19:12
Status
New
Announcement Sub Title
Clarification of Press Release on 1 July 2019 and Revised Press Release
Announcement Reference
SG190702OTHR3Z2C
Submitted By (Co./ Ind. Name)
Lew Kwang Ping
Designation
Executive Director and Chief Executive Officer
Description (Please provide a detailed description of the event in the box below)
Please refer to the following attachments:

1) Clarification of Press Release titled "Laboratory-Developed Tests by Biolidics Laboratory Partner in China to be reimbursed under China's National Basic Medical Insurance Program" dated 1 July 2019; and
2) Press Release dated 2 July 2019 on Biolidics' Laboratory Partner to provide Laboratory-Developed Test Service to Cancer Hospital in China in Clinical Trials to Test Status of PD-L1 in the Administration of Cancer Drug Treatments.

Attachments

Biolidics-Clarification Announcement on 1 July Press Release.pdf
Biolidics-Hunan LDTs-PDL_1-Press Release.pdf
Total size =1032K